AI Science Tracker

Multicenter targeted metabolomics and machine learning identify a six-metabolite rheumatoid-arthritis diagnostic panel

Tongren Hospital, Shanghai Jiao Tong University School of Medicine; The First Affiliated Hospital of Fujian Medical University; Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; The First Hospital of Lanzhou University; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 10 Nov 2025 · medicine

Discovery

Multicenter targeted metabolomics and machine learning identify a six-metabolite rheumatoid-arthritis diagnostic panel

Across seven cohorts and five medical centers, targeted metabolomics confirmed six metabolites—imidazoleacetic acid, ergothioneine, N-acetyl-L-methionine, 2-keto-3-deoxy-D-gluconic acid, 1-methylnicotinamide and dehydroepiandrosterone sulfate—as a panel for classifying rheumatoid arthritis against healthy controls and osteoarthritis. LASSO selected the six features, and logistic regression, random forest and XGBoost models were externally evaluated in geographically distinct cohorts; reported AUCs were 0.8375–0.9280 for RA versus healthy controls and 0.7340–0.8181 for RA versus osteoarthritis in three validation cohorts.

Technology: LASSO feature selection and logistic regression, random forest, support vector machine and XGBoost classifiers applied to untargeted and targeted metabolomics

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Across seven cohorts and five medical centers, targeted metabolomics confirmed six metabolites—imidazoleacetic acid, ergothioneine, N-acetyl-L-methionine, 2-keto-3-deoxy-D-gluconic acid, 1-methylnicotinamide and dehydroepiandrosterone sulfate—as a panel for classifying rheumatoid arthritis against healthy controls and osteoarthritis.
  • Still unknown: This is a cross-sectional case–control diagnostic study, not prospective screening or evidence of improved patient outcomes. The authors note that disease activity and treatment effects were not assessed, so prognostic and treatment-monitoring uses are not established. Performance varied across cohorts and was lower for RA-versus-OA than RA-versus-healthy-control classification; stronger platform-specific than sample-type effects were observed. Some mechanistic relevance of the six metabolites remains uncertain.
  • AI role: Machine-learning feature selection narrowed targeted-validated metabolites to a six-analyte panel, and supervised classifiers combined the measurements to distinguish RA from healthy controls and osteoarthritis in multiple independent cohorts. Targeted mass spectrometry provided absolute quantification; the models produced the reported cross-cohort diagnostic discrimination.

Evidence sources: https://link.springer.com/article/10.1186/s12967-025-07265-w

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 88 of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.